News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
ARYx Therapeutics, Inc. Says FDA Backs Anticlotting Agent Development Path
January 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- ARYx Therapeutics Inc said U.S. health regulators confirmed that the current development pathway for its experimental anticoagulant agent remains acceptable to seek regulatory approval.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
October 17, 2025
·
2 min read
·
Tristan Manalac
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
October 15, 2025
·
2 min read
·
Tristan Manalac
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
·
1 min read
·
Heather McKenzie